Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  erlotinib hydrochloride
Find trials that include:  Any drugs shown
Results 1-25 of 61 for your search:
Start Over
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TG4010.14/TIME, NCI-2013-00825, 8559, TG4010.14/TIME, 8559, NCT01383148
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1400, NCI-2014-00627, S1400A, S1400B, S1400C, S1400D, S1400E, NCT02154490
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating EGFR Mutation
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO28758, NCI-2014-00214, 2013-000868-29, NCT01887886
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 20 and over
Trial IDs: U31287-A-U301, NCI-2014-01446, NCT02134015
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated Lung Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: 18 and over
Trial IDs: 15296, NCI-2014-02441, 2013-004662-33, I3Y-MC-JPBK, NCT02152631
Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A081105, NCI-2014-01508, CALGB A081105, NCT02193282
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D5160C00007, NCI-2015-00219, 2014-002694-11, NCT02296125
Intensity-Modulated Radiation Therapy, Pemetrexed Disodium, and Erlotinib Hydrochloride in Treating Patients With Recurrent or Second Primary Head and Neck Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CCCWFU 60107, NCI-2009-01250, CCCWFU-IRB00003457, CDR0000578838, LILLY-CCCWFU-60107, NCT01580449, P30CA012197, NCT00573989
FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0432, NCI-2011-03444, NCT01455389
Alisertib and Erlotinib Hydrochloride in Treating Patients With Recurrent Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OER-TH-036, NCI-2011-03306, NCT01471964
Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Treating Patients with Stage IIIB-IV Non-Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CASE 8512, NCI-2013-00599, NCT01839955
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: 3475-021, NCI-2014-00482, NCT02039674
Pacritinib and Erlotinib Hydrochloride in Treating Patients with Metastatic or Locally Advanced Non-small Cell Lung Cancer after EGFR TKI Treatment
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201503052, NCI-2015-00399, NCT02342353
A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BGBC004, NCI-2015-00730, NCT02424617
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 6628, NCI-2010-00041, FHCRC-6628, UWCC-6628, UWHSD# 33866, GENENTECH-FHCRC-6628, NCT00733408
Erlotinib Hydrochloride and Panitumumab with or without Irinotecan Hydrochloride as Second Line Therapy in Patients with Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NU 07I4, NCI-2011-00222, OSI 4263s, NCT00940316
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB-IV Lung Cancer With a Light or Never Smoking History
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LCCC 0825, NCI-2013-01055, 09-0774, AVF4499s, UNC-LCCC-0825, NCT01344824
Combination Chemotherapy with or without Erlotinib Hydrochloride in Treating Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2009-0395, NCI-2011-03782, NCT01064479
Bevacizumab and Erlotinib Hydrochloride in Treating Patients with Hereditary Leiomyomatosis and Advanced Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-C-0114, NCI-2013-01459, 100114, P10628, NCT01130519
Radiation Therapy, Bevacizumab, Erlotinib Hydrochloride, or Temozolomide in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 18
Trial IDs: 10-321, NCI-2011-03059, DFCI 10-321, NCT01182350
Erlotinib Hydrochloride, Akt Inhibitor MK2206, Selumetinib, or Sorafenib Tosylate in Treating Patients with Previously Treated Stage III-IV Non-Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2009-0360, NCI-2011-01104, NCT01248247
Start Over